Riboflavin Offers A Targeted Strategy For Managing Hypertension In Patients With The MTHFR 677TT Genotype: A 4-y Follow-up
Notes for this study:
|Number of Subjects
In a four year followup to a study using 1.6mg riboflavin daily in subjects who were hypertensive and MTHFR 677TT homozygous, it was found that continued usage of riboflavin for the four years afterwards was able to reduce both systolic and diastolic blood pressure.
Although the study broke down analysis into different genomic groups, a placebo control in the same group (MTHFR 677TT) was not used in this followup.